Journal of Clinical Oncology
Articles in this Issue
Dexamethasone-associated hyperglycemia during chemotherapy in endometrial and ovarian cancer: A retrospective study.
e17583 Background: Dexamethasone is frequently administered during chemotherapy to prevent hypersensitivity reactions, nau...
Toxicity assessment clinic as an efficacious tool to provide fast care to oncology patients on systemic therapy by minimizing emergency department visits and streamlining admissions directly from the cancer clinics.
12124 Background: The Toxicity Assessment Clinic (TAC) at the Hudson Regional Cancer Centre was established to improve acc...
Estimated clinical benefits of timely biomarker testing and matched therapy in HR+/HER2– metastatic breast cancer in the United States: A population model.
e13049 Background: Targeted therapies for actionable genomic changes ( PI3K pathwa...
Radiation therapy utilization and survival associations in metastatic Merkel cell carcinoma in the immunotherapy era: A national database study.
e21561 Background: Immune checkpoint inhibitors (ICIs) have become the standard first-line systemic therapy for metastatic...
Treatment beyond progression after early radiographic changes on first-line ipilimumab/nivolumab in metastatic clear cell renal cell carcinoma.
e16506 Background: Ipilimumab/nivolumab (I/N) is a standard first-line (1L) regimen for metastatic clear cell renal cell c...
Emergency vs elective presentation as a care-delivery phenotype in presumed early-stage lung cancer: A National Inpatient analysis.
e23223 Background: Early-stage lung cancer is potentially curable with surgery, yet emergency or nonelective presentation...
Prognostic impact of cancer therapy–related cardiotoxicity on oncologic outcomes.
e24023 Background: Cancer therapy-related cardiotoxicity is a common complication of modern anticancer treatments and may...
Machine learning for prediction of postoperative pulmonary embolism after lung cancer surgery using routine perioperative variables.
e20522 Background: Postoperative pulmonary embolism (PE) remains a potentially fatal complication after lung cancer (LC) r...
Real-world conditional survival analysis of blastic plasmacytoid dendritic cell neoplasm.
e23332 Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic cancer that o...
Assessing the efficacy of cognitive behavioral therapy on anxiety, depression, and distress in people with cancer.
12100 Background: Patients with cancer frequently experience psychological impairments, including anxiety, depression, and...
Benchmarking the KEYNOTE-811 standard of care using AI-reconstructed external control arms in advanced gastric cancer.
4021 Background: Randomized controlled trials in rare cancers and biomarker-enriched populations face significant recruitm...
Comparative efficacy and safety of ROS1 tyrosine kinase inhibitors for advanced ROS1-positive non–small cell lung cancer: A systematic review and network meta-analysis.
e20733 Background: ROS1 rearrangements occur in approximately 1–2% of non–small cell lung cancers and define a clinically...
A multicenter analysis of CAR T-cell toxicities, target antigens, and dosing in solid and hematological malignancies.
e14513 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has showed remarkable efficacy in haematological malig...
Dose-dense weekly versus standard three-weekly paclitaxel in combination with carboplatin for resectable stage II-IV epithelial ovarian carcinoma: A retrospective cohort study.
5568 Background: Dose-dense weekly paclitaxel combined with carboplatin has demonstrated variable efficacy in first-line t...
A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress.
TPS6608 Background: Chronic myeloid leukemia (CML) is driven by the BCR::ABL1 oncogenic fusion protein. Although tyrosine...
Phase 3 study to assess the safety and efficacy of <sup>177</sup> Lu-girentuximab in advanced, relapsed, or recurrent ccRCC (LUTEON).
TPS4631 Background: A high unmet need remains for treatments that provide durable disease control while preserving quality...
Project IOTA (input optimization for tissue-based assays): Improving turnaround time (TAT) of mutation profiling for non-small cell lung cancer (NSCLC).
e23142 Background: Next-generation sequencing (NGS)–based biomarker testing is essential for guiding therapy in NSCLC, but...
Efficacy, safety, and cytokine profiling with addition of the toll-like receptor (TLR) 7/8 dual agonist EIK1001 to standard of care (SOC) first-line (1L) therapy: The phase 2 TeLuRide-005 trial in stage 4 NSCLC.
8568 Background: EIK1001 a TLR 7/8 dual agonist activates dendritic cells via both innate and adaptive pathways. This mech...
Correlative analysis between external and internal lymphedema in head and neck cancer survivors.
12120 Background: More than 75% of head and neck cancer (HNC) survivors develop lymphedema following cancer treatment. Lym...
Development and validation of a clinical-pathological tool for RS prediction: A practical alternative for resource-limited settings.
e13637 Background: International guidelines recommend the 21-gene Recurrence Score (RS) to guide adjuvant chemotherapy dec...
Novel accelerated partial breast irradiation simultaneous integrated boost technique: Rush experience.
e12536 Background: Breast cancer is the most common malignancy among U.S. women. Radiation therapy after lumpectomy reduce...
Modified soluble interleukin-2 receptor to ferritin ratio for diagnosis of lymphoma-associated hemophagocytic lymphohistiocytosis.
e19115 Background: Lymphoma-associated hemophagocytic lymphohistiocytosis (L-HLH) has higher mortality than HLH due to oth...
Metabotyping using early body weight velocity in lung cancer patients treated with pembrolizumab.
e20527 Background: PD-L1 tumor proportion score guides immune checkpoint inhibitor therapy in advanced non-small cell lung...
Survival outcomes of young patients with non-small cell lung cancer in Latin America: A real-world cohort study.
8067 Background: Young patients with non-small cell lung cancer (NSCLC) represent a distinct biological subgroup, frequent...
Real-world access to molecular diagnostics and immunotherapy for advanced melanoma in Syria.
e13635 Background: Melanoma is an aggressive skin malignancy with rising global incidence, for which checkpoint inhibitors...